Serial Salesman: Kailera CEO Ron Renaud has built and sold three biotechs, the last for $8.7 billion. “Companies get bought, they don’t get sold,” he says. But the obesity market’s frenzy could make Kailera a prime acquisition target.
Albie Colantonio for Forbes
Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is quickly emerging as a powerhouse pharmaceutical R&D center. After all, why spend millions trying to…
Continue Reading
News Source: www.forbes.com
Leave a Reply